Novartis said the National Medical Products Administration approved the
radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan injection)
in combination with androgen receptor pathway inhibitors (ARPI) for
PSMA‑positive metastatic hormone‑sensitive prostate cancer (mHSPC) in China.